| Detected | Trial | Change |
|---|---|---|
| 2026-06-09 | NCT07318558 A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer… |
Trial sites expanded: 77 -> 89 locations |
| 2026-06-09 | NCT07216703 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab… |
Trial sites expanded: 115 -> 125 locations |
| 2026-06-02 | NCT07216703 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab… |
Trial sites expanded: 107 -> 115 locations |
| 2026-05-30 | NCT07318558 A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer… |
Trial sites expanded: 60 -> 77 locations |
| 2026-05-27 | NCT07286149 A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer… |
Trial sites expanded: 12 -> 18 locations |
| 2026-05-23 | NCT07318558 A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer… |
Trial sites expanded: 50 -> 60 locations |
| 2026-05-23 | NCT07216703 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab… |
Trial sites expanded: 96 -> 107 locations |
| 2026-05-16 | NCT07216703 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab… |
Trial sites expanded: 91 -> 96 locations |
| 2026-05-16 | NCT07318558 A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer… |
Trial sites expanded: 41 -> 50 locations |
| 2026-05-15 | NCT07286149 A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer… |
Trial sites expanded: 4 -> 12 locations |
| 2026-05-14 | NCT06979596 A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) |
Trial sites expanded: 52 -> 55 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07216703 | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab… | Cervical Cancer | Recruiting |
| NCT07318558 | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer… | Ovarian Neoplasms | Recruiting |
| NCT06356311 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic… | Gastroesophageal Cancer | Active, Not Recruiting |
| NCT06132958 | Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial… | Endometrial Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT06979596 | A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | Malignant Neoplasm | Recruiting |
| NCT06780098 | Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated… | Lung Neoplasm | Recruiting |
| Phase 1/2 | |||
| NCT06445972 | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma… | Gastroesophageal Junction | Recruiting |
| NCT07286149 | A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer… | Lung Neoplasm Malignant | Recruiting |
| NCT07227597 | A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People… | Small Cell Lung Cancer Extensive Stage | Recruiting |
| Phase 1 | |||
| NCT06460961 | A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With… | Neoplasm Metastasis | Active, Not Recruiting |